Literature DB >> 2810112

The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction.

L Noronha-Blob1, V C Lowe, J S Peterson, R C Hanson.   

Abstract

The anticholinergic, antispasmodic and local anesthetic properties of agents indicated for the treatment of neurogenic bladder disorders were compared with known reference drugs in vitro and in cystometric studies in vivo in the guinea pig. Highly significant correlations (P = .0001) were found among the potencies of drugs to inhibit carbachol-induced isolated guinea pig detrusor muscle contraction in vitro and peak intravesical bladder pressure in vivo in the guinea pig cystometrogram, a test that provides the integrated micturition response in the intact animal. In contrast, there was no significant correlation (P greater than .5) among the potencies of the drugs to depress bladder contractile responses (in vitro and in vivo in the cystometrogram) and their potencies as antispasmodic or local anesthetic agents. Based on these correlations, we suggest that the anticholinergic component of the drugs' action is important in current effective therapies of bladder dysfunction. However, the possibility that other ancillary activities may also contribute to the specific mechanism of action of these agents in the urinary bladder is not ruled out.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810112

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Transdermal systems for overactive bladder: principles and practice.

Authors:  David R Staskin
Journal:  Rev Urol       Date:  2003

2.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

3.  Conformational studies on the four stereoisomers of the novel anticholinergic 4-(dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamide.

Authors:  H Oyasu; I Nakanishi; A Tanaka; K Murano; M Matsuo
Journal:  J Comput Aided Mol Des       Date:  1995-04       Impact factor: 3.686

4.  Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.

Authors:  R H Zobrist; B Schmid; A Feick; D Quan; S W Sanders
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

5.  Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.

Authors:  R Howard Zobrist; Danyi Quan; Heather M Thomas; Stephanie Stanworth; Steven W Sanders
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

6.  Characterization of the functional muscarinic receptors in the rat urinary bladder.

Authors:  P A Longhurst; R E Leggett; J A Briscoe
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.

Authors:  Nicholas V Nguyen; Jane Gralla; James Abbott; Anna L Bruckner
Journal:  Pediatr Dermatol       Date:  2018-01-15       Impact factor: 1.588

8.  Radiofrequency sacral rhizotomy for the management of intolerable neurogenic bladder in spinal cord injured patients.

Authors:  Kang Hee Cho; Sang Sook Lee
Journal:  Ann Rehabil Med       Date:  2012-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.